Non-antibiotic therapy for Clostridium difficile infection

被引:3
作者
Banerjee, S [1 ]
Lamont, JT [1 ]
机构
[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Gastroenterol, Boston, MA 02215 USA
关键词
D O I
10.1097/00001432-200006000-00003
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Treatment of Clostridium difficile infection with metronidazole or vancomycin is successful in the majority of cases, but relapse occurs in 15% to 20% of patients, and in some the infection can remain chronic for months or years. The use of non-antibiotic therapies for this infection is theoretically attractive, as they would enable the normal colonic microflora to be reconstituted which is a requirement for permanent eradication of this pathogen. Over the past decade a number of non-antibiotic approaches to eliminate or neutralize C. difficile or its toxins have been proposed, including probiotic therapy with non-pathogenic microorganisms and several forms of immunotherapy. These alternative approaches are in their infancy, but initial reports appear to support efficacy against this stubborn infection. Curr Opin Infect Dis 13:215-219. (C) 2000 Lippincott Williams & Wilkins.
引用
收藏
页码:215 / 219
页数:5
相关论文
共 64 条
  • [1] ENZYME-LINKED IMMUNOSORBENT-ASSAY (ELISA) FOR ANTIBODIES TO CLOSTRIDIUM-DIFFICILE TOXINS IN PATIENTS WITH PSEUDO-MEMBRANOUS COLITIS AND ANTIBIOTIC-ASSOCIATED DIARRHEA
    ARONSSON, B
    GRANSTROM, M
    MOLLBY, R
    NORD, CE
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 1983, 60 (03) : 341 - 350
  • [2] SERUM ANTIBODY-RESPONSE TO CLOSTRIDIUM DIFFICILE TOXINS IN PATIENTS WITH CLOSTRIDIUM DIFFICILE DIARRHEA
    ARONSSON, B
    GRANSTROM, M
    MOLLBY, R
    NORD, CE
    [J]. INFECTION, 1985, 13 (03) : 97 - 101
  • [3] BENNETT BG, 1996, NUTR TODAY S, V31, pS35
  • [4] TREATMENT OF RECURRENT CLOSTRIDIUM-DIFFICILE COLITIS WITH LACTOBACILLUS GG
    BILLER, JA
    KATZ, AJ
    FLORES, AF
    BUIE, TM
    GORBACH, SL
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 1995, 21 (02) : 224 - 226
  • [5] DISPOSITION KINETICS OF SACCHAROMYCES-BOULARDII IN MAN AND RAT
    BLEHAUT, H
    MASSOT, J
    ELMER, GW
    LEVY, RH
    [J]. BIOPHARMACEUTICS & DRUG DISPOSITION, 1989, 10 (04) : 353 - 364
  • [6] Isolation and characterization of two bacteriocins of Lactobacillus acidophilus LF221
    Bogovic-Matijasic, B
    Rogelj, I
    Nes, IF
    Holo, H
    [J]. APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 1998, 49 (05) : 606 - 612
  • [7] PROTECTION OF HAMSTERS AGAINST CLOSTRIDIUM-DIFFICILE ILEOCAECITIS BY PRIOR COLONIZATION WITH NON-PATHOGENIC STRAINS
    BORRIELLO, SP
    BARCLAY, FE
    [J]. JOURNAL OF MEDICAL MICROBIOLOGY, 1985, 19 (03) : 339 - 350
  • [8] SACCHAROMYCES-BOULARDII FOR CLOSTRIDIUM-DIFFICILE-ASSOCIATED ENTEROPATHIES IN INFANTS
    BUTS, JP
    CORTHIER, G
    DELMEE, M
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 1993, 16 (04) : 419 - 425
  • [9] Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum
    Castagliuolo, I
    LaMont, JM
    Nikulasson, ST
    Pothoulakis, C
    [J]. INFECTION AND IMMUNITY, 1996, 64 (12) : 5225 - 5232
  • [10] Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa
    Castagliuolo, I
    Riegler, MF
    Valenick, L
    LaMont, JT
    Pothoulakis, C
    [J]. INFECTION AND IMMUNITY, 1999, 67 (01) : 302 - 307